» Articles » PMID: 27341421

Depletion of Regulatory T Cells Induces High Numbers of Dendritic Cells and Unmasks a Subset of Anti-Tumour CD8+CD11c+ PD-1lo Effector T Cells

Overview
Journal PLoS One
Date 2016 Jun 25
PMID 27341421
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Natural regulatory T (Treg) cells interfere with multiple functions, which are crucial for the development of strong anti-tumour responses. In a model of 4T1 mammary carcinoma, depletion of CD25+Tregs results in tumour regression in Balb/c mice, but the mechanisms underlying this process are not fully understood. Here, we show that partial Treg depletion leads to the generation of a particular effector CD8 T cell subset expressing CD11c and low level of PD-1 in tumour draining lymph nodes. These cells have the capacity to migrate into the tumour, to kill DCs, and to locally regulate the anti-tumour response. These events are concordant with a substantial increase in CD11b+ resident dendritic cells (DCs) subsets in draining lymph nodes followed by CD8+ DCs. These results indicate that Treg depletion leads to tumour regression by unmasking an increase of DC subsets as a part of a program that optimizes the microenvironment by orchestrating the activation, amplification, and migration of high numbers of fully differentiated CD8+CD11c+PD1lo effector T cells to the tumour sites. They also indicate that a critical pattern of DC subsets correlates with the evolution of the anti-tumour response and provide a template for Treg depletion and DC-based therapy.

Citing Articles

High-Frequency Nanosecond Bleomycin Electrochemotherapy and its Effects on Changes in the Immune System and Survival.

Baleviciute A, Radzeviciute E, Zelvys A, Malysko-Ptasinske V, Novickij J, Zinkeviciene A Cancers (Basel). 2022; 14(24).

PMID: 36551739 PMC: 9776811. DOI: 10.3390/cancers14246254.


Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers.

Nebot-Bral L, Hollebecque A, Yurchenko A, de Forceville L, Danjou M, Jouniaux J J Immunother Cancer. 2022; 10(7).

PMID: 35896284 PMC: 9335020. DOI: 10.1136/jitc-2022-005059.


The Multifaceted Role of Regulatory T Cells in Breast Cancer.

Kos K, de Visser K Annu Rev Cancer Biol. 2021; 5:291-310.

PMID: 34632244 PMC: 7611782. DOI: 10.1146/annurev-cancerbio-042920-104912.


Prediagnostic breast milk DNA methylation alterations in women who develop breast cancer.

Salas L, Lundgren S, Browne E, Punska E, Anderton D, Karagas M Hum Mol Genet. 2020; 29(4):662-673.

PMID: 31943067 PMC: 7068171. DOI: 10.1093/hmg/ddz301.


Depleting tumor-associated Tregs via nanoparticle-mediated hyperthermia to enhance anti-CTLA-4 immunotherapy.

Chen H, Luan X, Paholak H, Burnett J, Stevers N, Sansanaphongpricha K Nanomedicine (Lond). 2019; 15(1):77-92.

PMID: 31868112 PMC: 7132783. DOI: 10.2217/nnm-2019-0190.


References
1.
Zhang N, Schroppel B, Lal G, Jakubzick C, Mao X, Chen D . Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. Immunity. 2009; 30(3):458-69. PMC: 2737741. DOI: 10.1016/j.immuni.2008.12.022. View

2.
Ahmadzadeh M, Johnson L, Heemskerk B, Wunderlich J, Dudley M, White D . Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009; 114(8):1537-44. PMC: 2927090. DOI: 10.1182/blood-2008-12-195792. View

3.
Slaney C, Kershaw M, Darcy P . Trafficking of T cells into tumors. Cancer Res. 2014; 74(24):7168-74. DOI: 10.1158/0008-5472.CAN-14-2458. View

4.
Li M, Wan Y, Flavell R . T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity. 2007; 26(5):579-91. DOI: 10.1016/j.immuni.2007.03.014. View

5.
Ronchese F, Hermans I . Killing of dendritic cells: a life cut short or a purposeful death?. J Exp Med. 2001; 194(5):F23-6. PMC: 2195940. DOI: 10.1084/jem.194.5.f23. View